@article{article_1403563, title={Effects of GDF-15 Level in Patients with Membranous Nephropathy}, journal={Experimed}, volume={14}, pages={40–45}, year={2024}, DOI={10.26650/experimed.1403563}, author={Adıkozalova, Aıda and Usta Akgül, Sebahat and Demir, Erol and Şentürk Çiftçi, Hayriye and Oğuz, Fatma Savran and Yazıcı, Halil and Kekik Çınar, Çiğdem}, keywords={Membranous nephropathy, GDF-15, ELISA}, abstract={Objective: Nephrotic syndrome is the most frequent cause of membranous nephropathy (MN) in adults. Growth differentiation factor (GDF)-15 is a cytokine released under stress and associated with increased incidence of chronic kidney disease and/or decreased renal function in conditions such as diabetic nephropathy, IgA nephropathy, lupus nephritis, and primary MN. The diagnosis of MN is made by biopsy, which is an invasive procedure. A non-invasive biomarker is needed for timely and risk-free diagnosis. This study aimed to estimate the GDF-15 level in patients with MN to determine if it can be used as a noninvasive biomarker for the diagnosis of MN. Materials and Methods: The study included 88 patients with MN. Sera were obtained from peripheral blood collected from the patients. GDF-15 levels were analyzed using enzyme-linked immunosorbent assay (ELISA). Results: GDF-15 level was high in older patients that in younger patients. The glomerular filtration rate was low in patients with increased GDF-15 levels. Furthermore, a decrease in GDF-15 levels was observed in patients in remission. Conclusion: GDF-15 level may be used as a biomarker to predict the progression of MN rather than a diagnostic biomarker.}, number={1}, publisher={Istanbul University}, organization={The study was supported by the approval of the Istanbul University Scientific Research and Project (BAP) commission with code number TYL-2018-32358.}